Valo Therapeutics Oy

Valo Therapeutics Secures €19M Funding to Advance Novel Cancer Immunotherapy Platform

2 months ago

• Valo Therapeutics has secured €19 million in funding from European and Australian investors to advance its PeptiCRAd cancer immunotherapy platform through Phase 1B clinical trials in Italy, Australia, and Germany. • The company will establish a new Italian subsidiary in Naples to conduct clinical trials, scale up virus manufacturing, and support research activities in Southern Italy. • PeptiCRAd technology uses tumor antigen-coated oncolytic viruses to enhance anti-tumor immune responses in solid tumors, potentially offering new treatment options for currently undruggable cancers.

Arvinas Advances Vepdegestrant into Phase 3 Trials for Breast Cancer and Updates Pipeline Milestones

4 months ago

• Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor. • Topline data from the Phase 3 VERITAC-2 monotherapy trial of vepdegestrant in second-line-plus ER+/HER2- metastatic breast cancer is anticipated in the first quarter of 2025. • Arvinas is set to present initial data from the Phase 1 trial of ARV-393 in B-cell lymphomas and file an IND application for a novel PROTAC KRAS G12D degrader in 2025. • Phase 1 trial with PROTAC LRRK2 degrader ARV-102 in patients with Parkinson’s disease has been initiated, with data expected to be presented in the first half of 2025.